BridgeBio Oncology Therapeutics (BBOT) Common Equity (2023 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Common Equity of $372.3 million for Q1 2026, down 9.44% sequentially from $411.1 million in Q4 2025, and up 286.11% YoY from $96.4 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Common Equity (2023 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Common Equity for 4 years, with the latest figure at $372.3 million in Q1 2026.
- Quarterly Common Equity rose 286.11% year-over-year to $372.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $372.3 million (up 286.11% YoY) and the FY2025 annual result came in at $411.1 million, up 330.13% from the prior year.
- Common Equity retreated to $372.3 million in Q1 2026 per BBOT's latest filing, from $411.1 million in the prior quarter.
- Over five years, Common Equity peaked at $446.7 million in Q3 2025 and troughed at -$227.7 million in Q2 2025.
- A 4-year average of $7.7 million and a median of -$136.2 million in 2024 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 380.58% in 2025, down 58.76% in 2025.
- Over 4 years, Common Equity stood at -$115.6 million in 2023, then slumped by 54.48% to -$178.6 million in 2024, then surged by 330.13% to $411.1 million in 2025, then declined by 9.44% to $372.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $372.3 million, $411.1 million, and $446.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 323.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 323.11 Mn |
| Mar 31, 2026 | 372.28 Mn |
| Dec 31, 2025 | 411.10 Mn |
| Sep 30, 2025 | 446.70 Mn |
| Jun 30, 2025 | -227.73 Mn |
| Mar 31, 2025 | -200.03 Mn |
| Dec 31, 2024 | -178.64 Mn |
| Sep 30, 2024 | -159.21 Mn |
| Jun 30, 2024 | -143.44 Mn |
| Mar 31, 2024 | -128.87 Mn |
| Dec 31, 2023 | -115.64 Mn |